Colorectal Cancer | Pharmacor | G7 | 2014

Treatment of colorectal cancer (CRC) represents a multibillion-dollar market. CRC is one of the most common forms of cancer in both men and women. Over the next ten years, the number of incident cases of CRC in the major pharmaceutical markets under study will increase as the aging population continues to expand and patients continue to be identified through screening efforts. Despite the establishment of an effective standard of care in the early-line setting, unmet need, and thus opportunity, remains for more-effective therapies in later-line treatment.

launch Related Market Assessment Reports